{"metadata": {"organization_names": [], "person_names_verified": ["nick gough", "christine mummery", "steven seinberg", "reubinoff kiryat", "benjamin eithan", "carl gulbrandsen", "dr einat zisman", "lily chan", "bernard tan", "michael p gray", "carl strachan", "lawrence chin", "fong chui yee", "ariffeen bongso", "carl e. gulbrandsen", "david w. pitt", "michael p. gray", "carl david strachan", "eugene khoo kay jin", "judith segall", "suzan lourdes", "lee suet-fern", "richard s. soroko", "lippenberger, thompson", "tan tiong gie bernard", "chu swee yeok", "michael d. west"], "organization_names_verified": ["hubrecht institute", "es cell international pte ltd.", "hadasit medical research services", "curis inc.", "monash investment holdings pty ltd monash", "es cell australia", "development company ltd", "hadasit medical research", "monash investment holdings pty ltd signatory", "monash investment holdings pty ltd", "curis inc", "nus technology holdings pte ltd signatory", "nus technology holdings pte ltd", "es cell australia limited signatory", "es cell australia limited", "pharmbio growth fund pte ltd", "biotime inc", "biomedical sciences investment fund pte ltd", "stamford law corporation", "soroko & gilbert", "wicell research institute inc", "wisconsin alumni research foundation", "wicell research institute", "allen & gledhill", "es cell international pte ltd", "biotime, inc.", "es cell international pte ltd signatory", "wicell research institute inc signatory", "biomedical sciences investment fund pte ltd signatory", "pharmbio growth fund pte ltd signatory"], "topics": [], "entities_rejected": [], "person_names": ["martin frederick pera", "benjamin eithan reubinoff", "david munro pitt", "heng mui keng terrace"], "agreement_id": "32a35243439cacb48e9255be31fca5349b5183d76e42d62bb42c8122d8275f18", "vars": {}, "terms": ["\"**Accredited Investor**\"", "\"**Closing Date**\"", "\"**Closing**\"", "\"**Confidential Information**\"", "\"**Disclosure Documents**\"", "\"**Other Shareholders**\"", "\"**Patent Application**\"", "\"**Purchase P**", "\"**Purchase P**rice**\"", "\"**Purchaser**\"", "\"**Registration Rights Agreement**\"", "\"**Regulation S**\"", "\"**Securities Act**\"", "\"**Series A1 ESI Preferred Shares**\"", "\"**Series A2 ESI Preferred Shares**\"", "\"**Series A3 ESI Preferred Shares**\"", "\"**U.S. Person**\"", "\"**United States**\"", "\"BioTime Shares**\"", "**\") shall be satisfied by the allotment and issue by Purchaser to the Other Shareholders of common shares, no par value, of Purchaser (the \"BioTime Shares**\"", "**(based on 0.00307680755416697 BioTime Shares per ESI Ordinary Share)**", "***Signatures Begin On Next Page***", "***Signatures Start on Following Page***", "**/s/ Ariffeen Bongso**", "**/s/ Benjamin Eithan Reubinoff**", "**/s/ Fong Chui Yee**", "**/s/ Martin Frederick Pera**", "**ADDITIONAL COVENANTS**", "**Accredited Investor Certification**", "**Accredited Investor**", "**Address and Nationality**", "**Amendments and Waivers**", "**Annex A**", "**Arbitration**", "**Authority**", "**Authority; Enforceability**", "**Breach of Closing Obligations**", "**CLOSING**", "**Certain Definitions**", "**Chief Executive Officer**", "**Chief Financial Officer**", "**Closing; Closing Date**", "**Conditions to Other Shareholders\u2019 Obligation to Close**", "**Conditions to Purchaser's Obligation to Close**", "**Conduct of Indemnification Proceedings**", "**Confidentiality**", "**Contribution**", "**Counterparts**", "**Definitions and Interpretations.**", "**Definitions**", "**Delays and Omissions**", "**Director**", "**Documents Delivered By Other Shareholders and Beneficial Shareholders**", "**Documents Delivered By Purchaser**", "**ESI:**", "**EXHIBIT B**", "**EXHIBIT C**", "**Enforceability**", "**Entire Agreement**", "**Entire Agreement; Amendment**", "**Expenses**", "**Foreign Resident Investor Certification**", "**Further Assurances**", "**GOVERNING LAW**", "**General; Securities Subject to this Agreement**", "**Governing Law**", "**Grant of Rights**", "**Headings**", "**Holders of Registrable Securities**", "**Indemnification by Designated Shareholders**", "**Indemnification by the Company**", "**Indemnification; Contribution**", "**Injunctive Remedies**", "**Interpretation**", "**Interpretation****", "**Investment Representations**", "**Jurisdiction**", "**MISCELLANEOUS**", "**Minimum Number of ESI Shares to Be Sold**", "**Miscellaneous**", "**Name and Particulars of Beneficial Shareholders**", "**Name and Particulars of Legal Shareholders**", "**Name and Particulars**", "**No Conflict**", "**No Litigation**", "**Non-Satisfaction /Waiver**", "**Non-U.S. Person Status**", "**Notice to Discontinue**", "**Notices**", "**Notices, etc.**", "**Number and Class of Principal ESI Shares**", "**Number of BioTime Shares per Principal ESI Share**", "**Number of BioTime Shares to be allotted and issued to Legal Shareholders**", "**Number of Other ESI Shares**", "**OF OTHER SHAREHOLDERS AND BENEFICIAL SHAREHOLDERS**", "**OTHER SHAREHOLDERS AND BENEFICIAL SHAREHOLDERS:**", "**Obligations of the Company**", "**Organization**", "**Other Agreements**", "**PRINCIPAL VENDORS**", "**PURCHASER**", "**Page**", "**Permitted Assignees; Third Party Beneficiaries**", "**President**", "**Private Placement**", "**Purchase Price**", "**REGISTRATION RIGHTS AGREEMENT**", "**REPRESENTATIONS AND WARRANTIES OF PURCHASER**", "**REPRESENTATIONS, WARRANTIES, AND COVENANTS**", "**Registrable Securities**", "**Registration Expenses**", "**Registration Procedures**", "**Registration of BioTime Shares**", "**Reports Under Exchange Act**", "**Resale Restrictions.**", "**Resale or Transfer of BioTime Securities**", "**Responsibility for Satisfaction**", "**Rules of Construction**", "**S-3 Registration**", "**SALE OF SHARES**", "**SEC Documents; Financial Statements**", "**Sale of Other ESI Shares**", "**Seller Requirements**", "**Severability**", "**Share Splits, etc**", "**Successors and Assigns**", "**TABLE OF CONTENTS**", "**TRANSFER AGREEMENT**", "**Taxes**", "**Termination of Shareholders\u2019 Agreement**", "**Third Party Rights**", "**Time of the Essence**", "**Title to Other ESI Shares**", "**Transfer of Registration Rights****", "**Validity of BioTime Shares**", "**Waiver of Pre-Emption Rights**", "**[Name and Address of Transferee]**", "**[Name and Address of Transferor]**", "**[Name of Transferee]**", "**[Name of Transferor]**", "**and to**", "**provided**", "**provided, however**", "**with a copy to**", "\u2019 fees and expenses) (each, a \u201cLiability\u201d and collectively, \u201c Liabilities\u201d", "\u201c**Beneficial Shareholders**\u201d", "\u201c**Business Day**\u201d", "\u201c**Company**\u201d", "\u201c**Designated Shareholder**\u201d", "\u201c**Designated Shareholders\u2019 Counsel**\u201d", "\u201c**ESI Ordinary Shares**\u201d", "\u201c**ESI Preferred Shares**\u201d", "\u201c**ESI Shares**\u201d", "\u201c**ESI**\u201d", "\u201c**Excepted Holder**\u201d", "\u201c**Excepted Shares**\u201d", "\u201c**Exchange Act**\u201d", "\u201c**Inspector**\u201d", "\u201c**Inspectors**\u201d", "\u201c**Liens**\u201d", "\u201c**Majority Other Shareholders**\u201d", "\u201c**Other ESI Shares**\u201d", "\u201c**Parties**\u201d", "\u201c**Pledgee**\u201d", "\u201c**Principal ESI Shares**\u201d", "\u201c**Principal Vendors**\u201d", "\u201c**Purchaser\u2019s Successor**\u201d", "\u201c**Records**\u201d", "\u201c**Registration Rights Agreement**\u201d", "\u201c**SEC Reports**\u201d", "\u201c**SHA Parties**\u201d", "\u201c**SIAC**\u201d", "\u201c**Shareholders\u2019 Agreement**\u201d", "\u201c**Transaction Documents**\u201d", "\u201c**Transferee**\u201d", "\u201c**Waived Other Shareholders Condition**\u201d", "\u201c**Waived Purchaser Condition**\u201d", "\u201c**related corporations**\u201d", "\u201c**subsidiary**\u201d", "\u201c**this Agreement**\u201d", "\u201cAgreement\u201d", "\u201cBioTime\u201d", "\u201cESI\u201d", "\u201cFamily Members\u201d", "\u201cIndemnified Party\u201d", "\u201cIndemnifying Party\u201d", "\u201cSelling Security Holder\u201d", "\u201caccredited investor.\u201d"]}}